Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25373236 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL15345823 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL15345786 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL25375053 | 0.86 | DUT (0.41) | DUT | |
| SCHEMBL432514 | 0.85 | DUT (0.39) | DUT | |
| SCHEMBL345800 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL11580466 | 0.83 | DUT (0.42) | DUT | |
| SCHEMBL25378318 | 0.83 | DUT (0.36) | DUT | |
| SCHEMBL5856290 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL3272074 | 0.81 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062785-B | Preparation method of ozagrel and intermediate thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-112062785-A | Preparation method of ozapimod and intermediate thereof | 广东东阳光药业有限公司 | 2020-12-11 | — | — | CN | claimed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137795-A1 | EXATECAN IMMUNOCONJUGATES | IMMUNOME INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617784-B2 | AKT inhibitor | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-0674625-A1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0674631-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1995025714-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1995-09-28 | — | — | WO | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1994013661-A1 | SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1994013644-A1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |
| EP-0507313-A1 | Polycyclic carbapenem compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | DUT 4761/4885 |
| US-12617784-B2 | AKT inhibitor | AKT2, AKT1, AKT3 | DUT 4383/4885 |
| US-20260137795-A1 | EXATECAN IMMUNOCONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDC1 | DUT 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.